Aprea Therapeutics
APRE
APRE
33 hedge funds and large institutions have $1.52M invested in Aprea Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
66% less capital invested
Capital invested by funds: $4.5M → $1.52M (-$2.98M)
Holders
33
Holding in Top 10
–
Calls
$477K
Puts
$10K
Top Buyers
| 1 | +$78.7K | |
| 2 | +$54K | |
| 3 | +$31.1K | |
| 4 |
D.E. Shaw & Co
New York
|
+$24.4K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$15K |
Top Sellers
| 1 | -$623K | |
| 2 | -$55K | |
| 3 | -$55K | |
| 4 |
Goldman Sachs
New York
|
-$54K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$43.2K |